How Microdosing GLP-1s Got Popular Despite these cons, microdosing GLP-1s seems to be everywhere on social media
After 9-12 months, the top quartile of patients achieved a BMI reduction of at least 11.2%, while the bottom quartile had less than 1.9% BMI reduction, or even experienced weight gain
A clinician can help identify any underlying conditions and, if needed, recommend targeted treatments
Considering the short half-life of small molecule oral GLP-1 receptor agonists, perhaps approaches to increase the duration of small molecules with a modified-release formulation may lead to improvements in long-term cardiovascular benefits
If you're ready to begin your weight loss journey with Semaglutide or Tirzepatide, book your personalized consultation with Wendy Pickett, RN, today
Implementation Strategy Adding all three GLOW peptides to a Retatrutide protocol creates significant complexity